Cigna (CI)
NYSE:CI
CI Stock Chart & Stats
$278.45
-$1.43(-0.51%)
At close: 4:00 PM EST
$278.45
-$1.43(-0.51%)
Day’s Range― - ―
52-Week Range$239.51 - $350.00
Previous CloseN/A
Volume191.22K
Average Volume (3M)1.69M
Market Cap
$73.42B
Enterprise Value$98.17B
Total Cash (Recent Filing)$7.68B
Total Debt (Recent Filing)$31.46B
Price to Earnings (P/E)12.3
Beta0.25
Next Earnings
Apr 30, 2026EPS Estimate
7.59Next Dividend Ex-DateN/A
Dividend Yield2.21%
Share Statistics
EPS (TTM)8.08
Shares Outstanding263,528,300
10 Day Avg. Volume1,353,103
30 Day Avg. Volume1,688,984
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)1.75
Price to Sales (P/S)0.27
P/FCF Ratio8.73
Enterprise Value/Market Cap1.34
Enterprise Value/Revenue0.36
Enterprise Value/Gross Profit3.78
Enterprise Value/Ebitda8.19
Forecast
1Y Price Target
$344.08Price Target Upside23.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)30.31
Revenue Forecast (FY)$283.12B
Bulls Say, Bears Say
Bulls Say
ASO And Stop‑loss Commercial StrategyA capital‑efficient strategy combining administrative services‑only contracts and stop‑loss insurance targets small and mid‑sized employers, enabling share gains in faster‑growing commercial segments and more profitable bundled service sales.
Leadership Continuity And Reaffirmed GuidanceA formal CEO succession plan that promotes an experienced internal executive, together with management reaffirmation of the near‑term financial outlook, reduces leadership uncertainty and supports operational continuity.
Regulatory Clarity For PBMFTC settlement and related regulatory actions remove a major legal overhang for the pharmacy benefit manager business, clarifying transition requirements and supporting a potential valuation re‑rating.
Bears Say
Commercial Market SaturationThe employer and individual commercial insurance market is largely penetrated with limited enrollment growth, constraining total addressable market expansion and weighing on valuation multiples versus government business.
PBM Model Durability And VisibilityVisibility into the durability and profitability of the rebate‑free pharmacy benefit model remains limited, creating uncertainty about the magnitude and timing of future PBM earnings contributions.
Reserve Volatility From Stop‑loss SeasonalityReported reserve movements driven by stop‑loss seasonality and lagged claim payments have produced material swings, creating uncertainty around future loss recognition and cash flow timing.
Cigna News
CI FAQ
What was Cigna’s price range in the past 12 months?
Cigna lowest stock price was $239.51 and its highest was $350.00 in the past 12 months.
What is Cigna’s market cap?
Cigna’s market cap is $73.42B.
When is Cigna’s upcoming earnings report date?
Cigna’s upcoming earnings report date is Apr 30, 2026 which is in 20 days.
How were Cigna’s earnings last quarter?
Cigna released its earnings results on Feb 05, 2026. The company reported $8.08 earnings per share for the quarter, beating the consensus estimate of $7.88 by $0.2.
Is Cigna overvalued?
According to Wall Street analysts Cigna’s price is currently Undervalued.
Does Cigna pay dividends?
Cigna pays a Quarterly dividend of $1.51 which represents an annual dividend yield of 2.21%. See more information on Cigna dividends here
What is Cigna’s EPS estimate?
Cigna’s EPS estimate is 7.59.
How many shares outstanding does Cigna have?
Cigna has 263,528,300 shares outstanding.
What happened to Cigna’s price movement after its last earnings report?
Cigna reported an EPS of $8.08 in its last earnings report, beating expectations of $7.88. Following the earnings report the stock price went up 4.718%.
Which hedge fund is a major shareholder of Cigna?
Currently, no hedge funds are holding shares in CI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cigna Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$344.08 (23.57% Upside)
$344.08 (23.57% Upside)
Blogger Sentiment
Bullish
CI Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 4.3%
Last 30 Days ▲ 4.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.14%
12-Months-Change
Fundamentals
Return on Equity
14.53%
Trailing 12-Months
Asset Growth
1.53%
Trailing 12-Months
Company Description
Cigna
The Cigna Group provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care delivery and management, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's Cigna Healthcare segment offers medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as individual health insurance plans to on and off the public exchanges; and health care coverage in its international markets, as well as health care benefits for mobile individuals and employees of multinational organizations. The company also offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for financing employer-paid future benefit obligations. It distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
CI Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call emphasized strong top-line and EPS growth in 2025, robust specialty and EverNorth performance, strategic clarity from the FTC settlement and PBM reform, and continued capital returns. Management acknowledged near-term charges, planned investments for the new rebate-free PBM model that will pressure cash flow and require execution, and elevated medical cost trends that influence MCR guidance. On balance, the positives (sustained revenue and earnings growth, specialty momentum, capital returns, regulatory clarity and a customer-oriented PBM model) outweigh the transitional and cost-related headwinds.View all CI earnings summariesCI Stock 12 Month Forecast
Average Price Target
$344.08
▲(23.57% Upside)
Technical Analysis
Ownership Overview
0.34% Insiders
28.83% Mutual Funds
22.51% Other Institutional Investors
25.51% Public Companies and Individual Investors